teclistamab approval for multiple myeloma treatment | ross firestone, md, phd | asco 2023
Published 1 year ago • 803 plays • Length 2:33Download video MP4
Download video MP3
Similar videos
-
2:34
what determines teclistamab response? | ross firestone, md, phd | ims 2023
-
2:13
changes in weight in induction therapy | ross firestone, md, phd | ims 2023
-
6:39
real world experiences of patients treated with teclistamab | shonali midha, md | ims 2023
-
1:12
exciting advances in myeloma treatment | timothy schmidt, md | asco 2023
-
22:21
tecvayli (teclistamab) everything you need to know
-
58:00
know your myeloma immunotherapy: teclistamab and other bispecifics
-
1:46
how teclistamab treatment affects quality of life | rakesh popat, md | eha 2022
-
10:20
understanding multiple myeloma (multiple myeloma explained clearly)
-
35:23
multiple myeloma update
-
14:31
teclistamab - guest lecture
-
6:59
teclistamab in combination with sub-q daratumumab and lenalidomide in myeloma pts: majestec-2
-
6:23
results of maintenance therapy in high-risk myeloma patients | ajay nooka, md, mph, facp | asco 2023
-
1:00
the recent fda approval of teclistamab for r/r multiple myeloma
-
15:43
elranatamab - upcoming myeloma therapy
-
0:45
fda approval of teclistamab for r/r multiple myeloma and the value of immunotherapies
-
17:55
talquetamab | therapies on the horizon
-
0:46
2-year follow-up of majestec-1: teclistamab in r/r multiple myeloma
-
15:05
overview of healthtree programs for multiple myeloma
-
4:48
in addition to your myeloma specialist what other healthcare professionals should you consider?
-
2:04
approval of teclistamab in triple-class refractory multiple myeloma
-
4:16
what is the monoclonal antibody talvey™ (talquetamab)?